Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
Before biotech companies have sales to report to investors, their share prices often live and die on the enthusiasm they can build about their ongoing clinical trials. And when those trials disappoint, biotech stocks can suffer mightily.
Consider Structure Therapeutics (NASDAQ: GPCR), which saw its shares fall 43% on Dec. 18 after publishing some clinical-trial data that the market disliked. But the trial wasn't necessarily a complete failure, and as skilled investors know, when there's a mismatch between sentiment and actual results, there's often opportunity to profit.
So let's examine whether Structure is worth buying now after its recent crash.
Source Fool.com
